Is there any survival benefit of additional chemotherapy (C) following adjuvant C in pancreatic cancer (PC) patients (pts) with postsurgery elevated CA19-9?

491Background: Pancreatectomy offers only potential for cure but is only possible in a minority of pts. Even in those pts who receive adjuvant C, majority of them succumb to death due to metastases. RTOG 9704 showed that post-surgery CA 19-9 levels are an important predictor of survival. ESPAC-3 showed that completion of all 6 cycles of adjuvant C was an independent prognostic factor. Any survival benefit of an intensified C strategy has not been demonstrated in pts with persistently ↑ CA19-9. The object of this study was to investigate any benefit of additional C following adjuvant in these pts. Methods: 25 pts with R0 surgery of PC who received adjuvant C with post-surgery ↑ CA 19-9 but no radiographic evidence of cancer were identified between 2005-2017. Either biopsy or PET scan determined recurrence of PC. Efficacy endpoints were overall survival (OS) and disease-free survival (DFS). Results: The Table summarizes results. Additional C included 5-FU, capecitabine, platins, irinotecan and nab-paclitaxe...